Respiratory and upper limb function as outcome measures in ambulant and non-ambulant subjects with Duchenne muscular dystrophy: A prospective multicentre study
•This study contributes to the natural history of DMD, linking the ambulant and non-ambulant phases.•Respiratory measurements, upper limb function, pinch and grip force are reported.•A composite score combining respiratory outcomes, upper limb function and strength is explored. The field of translat...
Saved in:
Published in | Neuromuscular disorders : NMD Vol. 29; no. 4; pp. 261 - 268 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , |
Format | Journal Article Web Resource |
Language | English |
Published |
England
Elsevier B.V
01.04.2019
|
Subjects | |
Online Access | Get full text |
ISSN | 0960-8966 1873-2364 1873-2364 |
DOI | 10.1016/j.nmd.2019.02.002 |
Cover
Loading…
Abstract | •This study contributes to the natural history of DMD, linking the ambulant and non-ambulant phases.•Respiratory measurements, upper limb function, pinch and grip force are reported.•A composite score combining respiratory outcomes, upper limb function and strength is explored.
The field of translational research in Duchenne muscular dystrophy (DMD) has been transformed in the last decade by a number of therapeutic targets, mostly studied in ambulant patients. A paucity of studies focus on measures that capture the non-ambulant stage of the disease, and the transition between the ambulant and non-ambulant phase. In this prospective natural history study, we report the results of a comprehensive assessment of respiratory, upper limb function and upper limb muscle strength in a group of 89 DMD boys followed in 3 European countries, 81 receiving corticosteroids, spanning a wide age range (5–18 years) and functional abilities, from ambulant (n = 60) to non-ambulant (n = 29). Respiratory decline could be detected in the early ambulatory phase using Peak Expiratory Flow percentage predicted (PEF%), despite glucocorticoid use (mean annual decline: 4.08, 95% CI [−7.44,−0.72], p = 0.02 in ambulant; 4.81, 95% CI [−6.79,−2.82], p < 0.001 in non-ambulant). FVC% captured disease progression in non-ambulant DMD subjects, with an annual loss of 5.47% (95% CI [−6.48,−4.45], p < 0.001). Upper limb function measured with the Performance of Upper Limb (PUL 1.2) showed an annual loss of 4.13 points (95% CI [−4.79,3.47], p < 0.001) in the non-ambulant cohort. Measures of upper limb strength (MyoGrip and MyoPinch) showed a continuous decline independent of the ambulatory status, when reported as percentage predicted (grip force −5.51%, 95% CI [−6.54,−4.48], p < 0.001 in ambulant and a slower decline −2.86%; 95% CI −3.29,−2.43, p < 0.001, in non-ambulant; pinch force: −2.66%, 95% CI [−3.82,−1.51], p < 0.001 in ambulant and −2.23%, 95% CI [−2.92,−1.53], p < 0.001 in non-ambulant). Furthermore, we also explored the novel concept of a composite endpoint by combining respiratory, upper limb function and force domains: we were able to identify clear clinical progression in patients in whom an isolated measurement of only one of these domains failed to appreciate the yearly change. Our study contributes to the field of natural history of DMD, linking the ambulant and non-ambulant phases of the disease, and suggests that composite scores should be explored further. |
---|---|
AbstractList | The field of translational research in Duchenne muscular dystrophy (DMD) has been transformed in the last decade by a number of therapeutic targets, mostly studied in ambulant patients. A paucity of studies focus on measures that capture the non-ambulant stage of the disease, and the transition between the ambulant and non-ambulant phase. In this prospective natural history study, we report the results of a comprehensive assessment of respiratory, upper limb function and upper limb muscle strength in a group of 89 DMD boys followed in 3 European countries, 81 receiving corticosteroids, spanning a wide age range (5-18 years) and functional abilities, from ambulant (n = 60) to non-ambulant (n = 29). Respiratory decline could be detected in the early ambulatory phase using Peak Expiratory Flow percentage predicted (PEF%), despite glucocorticoid use (mean annual decline: 4.08, 95% CI [-7.44,-0.72], p = 0.02 in ambulant; 4.81, 95% CI [-6.79,-2.82], p < 0.001 in non-ambulant). FVC% captured disease progression in non-ambulant DMD subjects, with an annual loss of 5.47% (95% CI [-6.48,-4.45], p < 0.001). Upper limb function measured with the Performance of Upper Limb (PUL 1.2) showed an annual loss of 4.13 points (95% CI [-4.79,3.47], p < 0.001) in the non-ambulant cohort. Measures of upper limb strength (MyoGrip and MyoPinch) showed a continuous decline independent of the ambulatory status, when reported as percentage predicted (grip force -5.51%, 95% CI [-6.54,-4.48], p < 0.001 in ambulant and a slower decline -2.86%; 95% CI -3.29,-2.43, p < 0.001, in non-ambulant; pinch force: -2.66%, 95% CI [-3.82,-1.51], p < 0.001 in ambulant and -2.23%, 95% CI [-2.92,-1.53], p < 0.001 in non-ambulant). Furthermore, we also explored the novel concept of a composite endpoint by combining respiratory, upper limb function and force domains: we were able to identify clear clinical progression in patients in whom an isolated measurement of only one of these domains failed to appreciate the yearly change. Our study contributes to the field of natural history of DMD, linking the ambulant and non-ambulant phases of the disease, and suggests that composite scores should be explored further.The field of translational research in Duchenne muscular dystrophy (DMD) has been transformed in the last decade by a number of therapeutic targets, mostly studied in ambulant patients. A paucity of studies focus on measures that capture the non-ambulant stage of the disease, and the transition between the ambulant and non-ambulant phase. In this prospective natural history study, we report the results of a comprehensive assessment of respiratory, upper limb function and upper limb muscle strength in a group of 89 DMD boys followed in 3 European countries, 81 receiving corticosteroids, spanning a wide age range (5-18 years) and functional abilities, from ambulant (n = 60) to non-ambulant (n = 29). Respiratory decline could be detected in the early ambulatory phase using Peak Expiratory Flow percentage predicted (PEF%), despite glucocorticoid use (mean annual decline: 4.08, 95% CI [-7.44,-0.72], p = 0.02 in ambulant; 4.81, 95% CI [-6.79,-2.82], p < 0.001 in non-ambulant). FVC% captured disease progression in non-ambulant DMD subjects, with an annual loss of 5.47% (95% CI [-6.48,-4.45], p < 0.001). Upper limb function measured with the Performance of Upper Limb (PUL 1.2) showed an annual loss of 4.13 points (95% CI [-4.79,3.47], p < 0.001) in the non-ambulant cohort. Measures of upper limb strength (MyoGrip and MyoPinch) showed a continuous decline independent of the ambulatory status, when reported as percentage predicted (grip force -5.51%, 95% CI [-6.54,-4.48], p < 0.001 in ambulant and a slower decline -2.86%; 95% CI -3.29,-2.43, p < 0.001, in non-ambulant; pinch force: -2.66%, 95% CI [-3.82,-1.51], p < 0.001 in ambulant and -2.23%, 95% CI [-2.92,-1.53], p < 0.001 in non-ambulant). Furthermore, we also explored the novel concept of a composite endpoint by combining respiratory, upper limb function and force domains: we were able to identify clear clinical progression in patients in whom an isolated measurement of only one of these domains failed to appreciate the yearly change. Our study contributes to the field of natural history of DMD, linking the ambulant and non-ambulant phases of the disease, and suggests that composite scores should be explored further. •This study contributes to the natural history of DMD, linking the ambulant and non-ambulant phases.•Respiratory measurements, upper limb function, pinch and grip force are reported.•A composite score combining respiratory outcomes, upper limb function and strength is explored. The field of translational research in Duchenne muscular dystrophy (DMD) has been transformed in the last decade by a number of therapeutic targets, mostly studied in ambulant patients. A paucity of studies focus on measures that capture the non-ambulant stage of the disease, and the transition between the ambulant and non-ambulant phase. In this prospective natural history study, we report the results of a comprehensive assessment of respiratory, upper limb function and upper limb muscle strength in a group of 89 DMD boys followed in 3 European countries, 81 receiving corticosteroids, spanning a wide age range (5–18 years) and functional abilities, from ambulant (n = 60) to non-ambulant (n = 29). Respiratory decline could be detected in the early ambulatory phase using Peak Expiratory Flow percentage predicted (PEF%), despite glucocorticoid use (mean annual decline: 4.08, 95% CI [−7.44,−0.72], p = 0.02 in ambulant; 4.81, 95% CI [−6.79,−2.82], p < 0.001 in non-ambulant). FVC% captured disease progression in non-ambulant DMD subjects, with an annual loss of 5.47% (95% CI [−6.48,−4.45], p < 0.001). Upper limb function measured with the Performance of Upper Limb (PUL 1.2) showed an annual loss of 4.13 points (95% CI [−4.79,3.47], p < 0.001) in the non-ambulant cohort. Measures of upper limb strength (MyoGrip and MyoPinch) showed a continuous decline independent of the ambulatory status, when reported as percentage predicted (grip force −5.51%, 95% CI [−6.54,−4.48], p < 0.001 in ambulant and a slower decline −2.86%; 95% CI −3.29,−2.43, p < 0.001, in non-ambulant; pinch force: −2.66%, 95% CI [−3.82,−1.51], p < 0.001 in ambulant and −2.23%, 95% CI [−2.92,−1.53], p < 0.001 in non-ambulant). Furthermore, we also explored the novel concept of a composite endpoint by combining respiratory, upper limb function and force domains: we were able to identify clear clinical progression in patients in whom an isolated measurement of only one of these domains failed to appreciate the yearly change. Our study contributes to the field of natural history of DMD, linking the ambulant and non-ambulant phases of the disease, and suggests that composite scores should be explored further. The field of translational research in Duchenne muscular dystrophy (DMD) has been transformed in the last decade by a number of therapeutic targets, mostly studied in ambulant patients. A paucity of studies focus on measures that capture the non-ambulant stage of the disease, and the transition between the ambulant and non-ambulant phase. In this prospective natural history study, we report the results of a comprehensive assessment of respiratory, upper limb function and upper limb muscle strength in a group of 89 DMD boys followed in 3 European countries, 81 receiving corticosteroids, spanning a wide age range (5-18 years) and functional abilities, from ambulant (n = 60) to non-ambulant (n = 29). Respiratory decline could be detected in the early ambulatory phase using Peak Expiratory Flow percentage predicted (PEF%), despite glucocorticoid use (mean annual decline: 4.08, 95% CI [-7.44,-0.72], p = 0.02 in ambulant; 4.81, 95% CI [-6.79,-2.82], p < 0.001 in non-ambulant). FVC% captured disease progression in non-ambulant DMD subjects, with an annual loss of 5.47% (95% CI [-6.48,-4.45], p < 0.001). Upper limb function measured with the Performance of Upper Limb (PUL 1.2) showed an annual loss of 4.13 points (95% CI [-4.79,3.47], p < 0.001) in the non-ambulant cohort. Measures of upper limb strength (MyoGrip and MyoPinch) showed a continuous decline independent of the ambulatory status, when reported as percentage predicted (grip force -5.51%, 95% CI [-6.54,-4.48], p < 0.001 in ambulant and a slower decline -2.86%; 95% CI -3.29,-2.43, p < 0.001, in non-ambulant; pinch force: -2.66%, 95% CI [-3.82,-1.51], p < 0.001 in ambulant and -2.23%, 95% CI [-2.92,-1.53], p < 0.001 in non-ambulant). Furthermore, we also explored the novel concept of a composite endpoint by combining respiratory, upper limb function and force domains: we were able to identify clear clinical progression in patients in whom an isolated measurement of only one of these domains failed to appreciate the yearly change. Our study contributes to the field of natural history of DMD, linking the ambulant and non-ambulant phases of the disease, and suggests that composite scores should be explored further. The field of translational research in Duchenne muscular dystrophy (DMD) has been transformed in the last decade by a number of therapeutic targets, mostly studied in ambulant patients. A paucity of studies focus on measures that capture the non-ambulant stage of the disease, and the transition between the ambulant and non-ambulant phase. In this prospective natural history study, we report the results of a comprehensive assessment of respiratory, upper limb function and upper limb muscle strength in a group of 89 DMD boys followed in 3 European countries, 81 receiving corticosteroids, spanning a wide age range (5-18 years) and functional abilities, from ambulant (n=60) to non-ambulant (n=29). Respiratory decline could be detected in the early ambulatory phase using Peak Expiratory Flow percentage predicted (PEF%), despite glucocorticoid use (mean annual decline: 4.08, 95% CI [-7.44,-0.72], p=0.02 in ambulant; 4.81, 95% CI [-6.79,-2.82], p < 0.001 in non-ambulant). FVC% captured disease progression in non-ambulant DMD subjects, with an annual loss of 5.47% (95% CI [-6.48,-4.45], p < 0.001). Upper limb function measured with the Performance of Upper Limb (PUL 1.2) showed an annual loss of 4.13 points (95% CI [-4.79,3.47], p < 0.001) in the non-ambulant cohort. Measures of upper limb strength (MyoGrip and MyoPinch) showed a continuous decline independent of the ambulatory status, when reported as percentage predicted (grip force -5.51%, 95% CI [-6.54,-4.48], p < 0.001 in ambulant and a slower decline -2.86%; 95% CI -3.29,-2.43, p < 0.001, in non-ambulant; pinch force: -2.66%, 95% CI [-3.82,-1.51], p < 0.001 in ambulant and -2.23%, 95% CI [-2.92,-1.53], p < 0.001 in non-ambulant). Furthermore, we also explored the novel concept of a composite endpoint by combining respiratory, upper limb function and force domains: we were able to identify clear clinical progression in patients in whom an isolated measurement of only one of these domains failed to appreciate the yearly change. Our study contributes to the field of natural history of DMD, linking the ambulant and non-ambulant phases of the disease, and suggests that composite scores should be explored further. |
Author | Ridout, D. Mayhew, A. Butler, J. Jansen, M. Verschuuren, J.J.G.M. Ricotti, V. Eagle, M. Decostre, V. Voit, T. Guglieri, M. Niks, E.H. Van der Holst, M. Muntoni, F. Domingos, J. de Groot, I.J.M. Selby, V. Servais, L. Straub, V. Hogrel, J.Y. |
Author_xml | – sequence: 1 givenname: V. surname: Ricotti fullname: Ricotti, V. email: v.ricotti@ucl.ac.uk organization: NIHR Great Ormond Street Hospital Biomedical Research Centre, Great Ormond Street Institute of Child Health, Great Ormond Street Hospital Trust, University College London, London, UK – sequence: 2 givenname: V. surname: Selby fullname: Selby, V. organization: NIHR Great Ormond Street Hospital Biomedical Research Centre, Great Ormond Street Institute of Child Health, Great Ormond Street Hospital Trust, University College London, London, UK – sequence: 3 givenname: D. surname: Ridout fullname: Ridout, D. organization: NIHR Great Ormond Street Hospital Biomedical Research Centre, Great Ormond Street Institute of Child Health, Great Ormond Street Hospital Trust, University College London, London, UK – sequence: 4 givenname: J. surname: Domingos fullname: Domingos, J. organization: Dubowitz Neuromuscular Centre, UCL Great Ormond Street Institute of Child Health, Great Ormond Street Hospital Trust, London, UK – sequence: 5 givenname: V. surname: Decostre fullname: Decostre, V. organization: Groupe Hospitalier Pitié Salpêtrière, Institut de Myologie, Paris, France – sequence: 6 givenname: A. surname: Mayhew fullname: Mayhew, A. organization: John Walton Muscular Dystrophy Research Centre, Newcastle University, Newcastle, UK – sequence: 7 givenname: M. surname: Eagle fullname: Eagle, M. organization: John Walton Muscular Dystrophy Research Centre, Newcastle University, Newcastle, UK – sequence: 8 givenname: J. surname: Butler fullname: Butler, J. organization: Dubowitz Neuromuscular Centre, UCL Great Ormond Street Institute of Child Health, Great Ormond Street Hospital Trust, London, UK – sequence: 9 givenname: M. surname: Guglieri fullname: Guglieri, M. organization: John Walton Muscular Dystrophy Research Centre, Newcastle University, Newcastle, UK – sequence: 10 givenname: M. orcidid: 0000-0002-0797-5711 surname: Van der Holst fullname: Van der Holst, M. organization: Leiden University Medical Centre, Leiden, The Netherlands – sequence: 11 givenname: M. surname: Jansen fullname: Jansen, M. organization: Department of Rehabilitation, Donders Centre of Neuroscience, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands – sequence: 12 givenname: J.J.G.M. orcidid: 0000-0002-4572-1501 surname: Verschuuren fullname: Verschuuren, J.J.G.M. organization: Leiden University Medical Centre, Leiden, The Netherlands – sequence: 13 givenname: I.J.M. surname: de Groot fullname: de Groot, I.J.M. organization: Department of Rehabilitation, Donders Centre of Neuroscience, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands – sequence: 14 givenname: E.H. orcidid: 0000-0001-5892-5143 surname: Niks fullname: Niks, E.H. organization: Leiden University Medical Centre, Leiden, The Netherlands – sequence: 15 givenname: L. surname: Servais fullname: Servais, L. organization: Groupe Hospitalier Pitié Salpêtrière, Institut de Myologie, Paris, France – sequence: 16 givenname: V. surname: Straub fullname: Straub, V. organization: John Walton Muscular Dystrophy Research Centre, Newcastle University, Newcastle, UK – sequence: 17 givenname: T. surname: Voit fullname: Voit, T. organization: NIHR Great Ormond Street Hospital Biomedical Research Centre, Great Ormond Street Institute of Child Health, Great Ormond Street Hospital Trust, University College London, London, UK – sequence: 18 givenname: J.Y. orcidid: 0000-0003-0045-7505 surname: Hogrel fullname: Hogrel, J.Y. organization: Groupe Hospitalier Pitié Salpêtrière, Institut de Myologie, Paris, France – sequence: 19 givenname: F. surname: Muntoni fullname: Muntoni, F. email: f.muntoni@ucl.ac.uk organization: NIHR Great Ormond Street Hospital Biomedical Research Centre, Great Ormond Street Institute of Child Health, Great Ormond Street Hospital Trust, University College London, London, UK |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/30852071$$D View this record in MEDLINE/PubMed |
BookMark | eNqFkctu1DAUhiNURKeFB2CDvGSTwZeME8OqKlepEhKCteXYJx0PiR18aZWn4VVxmJZFF2Vl6-j7juz_P6tOnHdQVS8J3hJM-JvD1k1mSzERW0y3GNMn1YZ0Lasp481JtcGC47oTnJ9WZzEeMCa7lrfPqlOGux3FLdlUv79BnG1QyYcFKWdQnmcIaLRTj4bsdLLeIRWRz0n7CdAEKuYAEdkynvo8Kpf-euVp9b9BzP0BdIro1qY9ep_1Hpwrco66AAGZJabg5_3yFl2gOfg4F9rerMSYrAaXAqCYslmeV08HNUZ4cXeeVz8-fvh--bm--vrpy-XFVa2bpk11Nwx6IGqgDKAhuhVCGGi5Yo3oYQDd4p3mxHDomTCs31GiFJB-6BojmBgIO6_Yce9o4RqkD72VN1R6ZY_3PF5LpWUPklLeSdo0mK3W66NV_vArQ0xyslHDWEIAn6OkRGBCMecr-uoOzf0ERs7BTios8r6KArRHQJc8YoBBapvUmn8Kyo6SYLmWLg-ylC7X0iWmspReTPLAvF_-mPPu6EAJ9cZCkFFbcBqMDaULabx91BYPbD1aZ7Uaf8LyH_cPHZvcTA |
CitedBy_id | crossref_primary_10_1159_000514730 crossref_primary_10_3233_JND_230019 crossref_primary_10_1016_j_nmd_2021_07_015 crossref_primary_10_1016_j_omtm_2020_06_016 crossref_primary_10_1089_nat_2021_0043 crossref_primary_10_1002_acn3_51046 crossref_primary_10_3233_JND_210746 crossref_primary_10_1111_ene_16267 crossref_primary_10_1515_jpem_2025_0061 crossref_primary_10_2217_epi_2020_0052 crossref_primary_10_1007_s00115_020_01019_3 crossref_primary_10_1097_PEP_0000000000000922 crossref_primary_10_1186_s13023_021_02047_1 crossref_primary_10_1016_j_nmd_2023_10_003 crossref_primary_10_1038_s41591_022_02045_1 crossref_primary_10_3390_biom13071108 crossref_primary_10_3390_proteomes12010004 crossref_primary_10_1212_WNL_0000000000011051 crossref_primary_10_1371_journal_pone_0239064 crossref_primary_10_1055_s_0042_1758757 crossref_primary_10_3390_ijerph192315675 crossref_primary_10_1016_j_nmd_2019_10_008 crossref_primary_10_1590_1984_0462_2021_39_2020045 crossref_primary_10_1212_WNL_0000000000013246 crossref_primary_10_3389_fgene_2021_759994 crossref_primary_10_1016_j_nmd_2023_07_003 crossref_primary_10_1111_echo_15460 crossref_primary_10_1016_j_bjpt_2020_05_012 crossref_primary_10_3390_children10040746 crossref_primary_10_1038_s41582_023_00823_0 crossref_primary_10_1007_s00424_021_02623_1 crossref_primary_10_1007_s00415_020_09800_9 crossref_primary_10_1148_radiol_2020192210 |
Cites_doi | 10.1371/journal.pone.0162542 10.1002/ana.23528 10.1016/j.nmd.2012.10.022 10.1016/S1474-4422(09)70271-6 10.1016/S0140-6736(15)60025-3 10.1371/journal.pone.0199223 10.1016/j.nmd.2015.07.009 10.1371/journal.pone.0083400 10.1183/09031936.00080312 10.1016/j.nmd.2011.02.016 10.1016/j.nmd.2013.05.008 10.1212/WNL.0000000000002891 10.1016/j.jacc.2016.02.081 10.1016/S1474-4422(18)30025-5 10.1002/mus.24894 10.1152/physrev.00028.2001 10.1002/ppul.10217 10.1164/rccm.201703-0507WS 10.1111/dmcn.12213 10.1183/09031936.05.00034805 10.1542/peds.2018-0333J 10.1016/j.nmd.2013.11.014 10.1002/ppul.22688 10.3233/JND-140002 10.1186/s12891-015-0612-4 10.1016/S1474-4422(18)30026-7 10.3233/JND-150100 10.1016/j.nmd.2018.07.004 10.1002/ppul.22847 10.1177/0883073810371004 10.1002/mus.25089 10.1002/ppul.23172 10.1016/S0960-8966(02)00140-2 10.1016/S1474-4422(18)30024-3 10.1212/WNL.0000000000002464 |
ContentType | Journal Article Web Resource |
Copyright | 2019 Elsevier B.V. Copyright © 2019 Elsevier B.V. All rights reserved. |
Copyright_xml | – notice: 2019 Elsevier B.V. – notice: Copyright © 2019 Elsevier B.V. All rights reserved. |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 Q33 |
DOI | 10.1016/j.nmd.2019.02.002 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic Université de Liège - Open Repository and Bibliography (ORBI) |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1873-2364 |
EndPage | 268 |
ExternalDocumentID | oai_orbi_ulg_ac_be_2268_244031 30852071 10_1016_j_nmd_2019_02_002 S0960896618313798 |
Genre | Research Support, Non-U.S. Gov't Multicenter Study Journal Article |
GeographicLocations | Europe |
GeographicLocations_xml | – name: Europe |
GroupedDBID | --- --K --M .1- .FO .GJ .~1 0R~ 123 1B1 1P~ 1RT 1~. 1~5 29N 4.4 457 4G. 53G 5VS 7-5 71M 8P~ 9JM AABNK AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AATTM AAXKI AAXLA AAXUO AAYWO ABBQC ABCQJ ABFNM ABFRF ABJNI ABLJU ABMAC ABMZM ABTEW ABWVN ABXDB ACDAQ ACGFO ACGFS ACIEU ACIUM ACRLP ACRPL ACVFH ADBBV ADCNI ADEZE ADMUD ADNMO ADVLN AEBSH AEFWE AEIPS AEKER AENEX AEUPX AEVXI AFJKZ AFPUW AFRHN AFTJW AFXIZ AGCQF AGHFR AGQPQ AGUBO AGWIK AGYEJ AHHHB AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRLJ AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV CS3 DU5 EBS EFJIC EFKBS EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HDW HMK HMO HMQ HVGLF HZ~ IHE J1W KOM LX8 M29 M2V M41 MO0 MOBAO N9A O-L O9- OAUVE OP~ OZT P-8 P-9 P2P PC. Q38 R2- ROL RPZ SAE SCC SDF SDG SDP SEL SES SEW SNS SPCBC SSH SSN SSZ T5K UHS UNMZH WUQ Z5R ~G- AACTN AADPK AAIAV ABLVK ABYKQ AFCTW AFKWA AJBFU AJOXV AMFUW EFLBG LCYCR RIG ZA5 AAYXX AGRNS CITATION CGR CUY CVF ECM EIF NPM 7X8 Q33 |
ID | FETCH-LOGICAL-c447t-8ffcf1af23ee41c7999de76a349befec705c61d6eb39d3b521aae1bf84d939f13 |
IEDL.DBID | .~1 |
ISSN | 0960-8966 1873-2364 |
IngestDate | Fri Jul 18 15:30:46 EDT 2025 Thu Jul 10 23:00:28 EDT 2025 Thu Apr 03 06:58:30 EDT 2025 Thu Apr 24 22:55:15 EDT 2025 Tue Jul 01 01:07:19 EDT 2025 Fri Feb 23 02:13:50 EST 2024 Tue Aug 26 16:46:51 EDT 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 4 |
Keywords | pulmonary function peak expiratory flow Composite endpoint Upper limb function and strength Duchenne muscular dystrophy forced vital capacity |
Language | English |
License | Copyright © 2019 Elsevier B.V. All rights reserved. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c447t-8ffcf1af23ee41c7999de76a349befec705c61d6eb39d3b521aae1bf84d939f13 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 scopus-id:2-s2.0-85062401627 |
ORCID | 0000-0002-4572-1501 0000-0001-5892-5143 0000-0003-0045-7505 0000-0002-0797-5711 |
PMID | 30852071 |
PQID | 2190120661 |
PQPubID | 23479 |
PageCount | 8 |
ParticipantIDs | liege_orbi_v2_oai_orbi_ulg_ac_be_2268_244031 proquest_miscellaneous_2190120661 pubmed_primary_30852071 crossref_citationtrail_10_1016_j_nmd_2019_02_002 crossref_primary_10_1016_j_nmd_2019_02_002 elsevier_sciencedirect_doi_10_1016_j_nmd_2019_02_002 elsevier_clinicalkey_doi_10_1016_j_nmd_2019_02_002 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | April 2019 2019-04-00 20190401 2019-04 |
PublicationDateYYYYMMDD | 2019-04-01 |
PublicationDate_xml | – month: 04 year: 2019 text: April 2019 |
PublicationDecade | 2010 |
PublicationPlace | England |
PublicationPlace_xml | – name: England |
PublicationTitle | Neuromuscular disorders : NMD |
PublicationTitleAlternate | Neuromuscul Disord |
PublicationYear | 2019 |
Publisher | Elsevier B.V |
Publisher_xml | – name: Elsevier B.V |
References | Seferian, Moraux, Annoussamy (bib0034) 2015; 10 Ricotti, Evans, Sinclair (bib0041) 2016; 11 Moxley, Pandya, Ciafaloni, Fox, Campbell (bib0005) 2010; 25 Buyse, Goemans, van den Hauwe (bib0017) 2011; 21 Hogrel, Wary, Moraux (bib0040) 2016; 86 Excellence N-NIfHaC. Ataluren for Treating Duchenne Muscular Dystrophy with a Nonsense Mutation in the Dystrophin Gene. In: Excellence N-N I f H a C, 2016. Connolly, Florence, Zaidman (bib0038) 2016; 54 Matthews, Brassington, Kuntzer, Jichi, Manzur (bib0013) 2016; 5 Buyse, Voit, Schara (bib0019) 2015; 385 Birnkrant, Bushby, Bann (bib0010) 2018; 17 Mayer, Finkel, Rummey (bib0037) 2015; 50 Apkon, Alman, Birnkrant (bib0006) 2018; 142 Pane, Coratti, Brogna (bib0033) 2018; 13 Blake, Weir, Newey, Davies (bib0004) 2002; 82 LoMauro, D'Angelo, Aliverti (bib0009) 2015; 11 Eagle, Baudouin, Chandler, Giddings, Bullock, Bushby (bib0007) 2002; 12 Servais, Deconinck, Moraux (bib0028) 2013; 23 (bib0035) 2017 2017. Pane, Mazzone, Fanelli (bib0024) 2014; 24 McDonald, Gordish-Dressman, Henricson (bib0021) 2018; 28 Bushby, Finkel, Birnkrant (bib0027) 2010; 9 Domenech-Clar, Lopez-Andreu, Compte-Torrero (bib0031) 2003; 35 Han, de Bie, Nicorici (bib0026) 2016; 53 Finder, Mayer, Sheehan (bib0020) 2017; 196 Bello, Morgenroth, Gordish-Dressman (bib0043) 2016; 87 Pane, Mazzone, Sormani (bib0025) 2014; 9 Birnkrant, Bushby, Bann (bib0011) 2018; 17 Ricotti, Ridout, Pane (bib0042) 2016; 87 Hogrel (bib0029) 2015; 16 Buyse, Voit, Schara (bib0039) 2015; 385 Mendell, Shilling, Leslie (bib0002) 2012; 71 Buyse, Goemans, van den Hauwe, Meier (bib0018) 2013; 48 Pane, Fanelli, Mazzone (bib0023) 2015; 25 Kamdar, Garry (bib0008) 2016; 67 Ellis, Vroom, Muntoni (bib0003) 2013; 23 Mayhew, Mazzone, Eagle (bib0022) 2013; 55 Jean, Mah, Dykeman, Day, Pringsheim, Jette (bib0001) 2014; 24 Quanjer, Stanojevic, Cole (bib0032) 2012; 40 Birnkrant, Bushby, Bann (bib0012) 2018; 17 Miller, Hankinson, Brusasco (bib0030) 2005; 26 van den Bergen, Ginjaar, Niks, Aartsma-Rus, Verschuuren (bib0044) 2014; 1 Servais, Montus, Guiner (bib0045) 2015; 2 (bib0016) 2016 Khirani, Ramirez, Aubertin (bib0036) 2014; 49 Administration USFaD Han (10.1016/j.nmd.2019.02.002_bib0026) 2016; 53 (10.1016/j.nmd.2019.02.002_bib0016) 2016 Apkon (10.1016/j.nmd.2019.02.002_bib0006) 2018; 142 Hogrel (10.1016/j.nmd.2019.02.002_bib0040) 2016; 86 Domenech-Clar (10.1016/j.nmd.2019.02.002_bib0031) 2003; 35 Moxley (10.1016/j.nmd.2019.02.002_bib0005) 2010; 25 Bushby (10.1016/j.nmd.2019.02.002_bib0027) 2010; 9 Mayer (10.1016/j.nmd.2019.02.002_bib0037) 2015; 50 Eagle (10.1016/j.nmd.2019.02.002_bib0007) 2002; 12 Kamdar (10.1016/j.nmd.2019.02.002_bib0008) 2016; 67 Buyse (10.1016/j.nmd.2019.02.002_bib0018) 2013; 48 Pane (10.1016/j.nmd.2019.02.002_bib0024) 2014; 24 Birnkrant (10.1016/j.nmd.2019.02.002_bib0011) 2018; 17 Pane (10.1016/j.nmd.2019.02.002_bib0033) 2018; 13 Ellis (10.1016/j.nmd.2019.02.002_bib0003) 2013; 23 Seferian (10.1016/j.nmd.2019.02.002_bib0034) 2015; 10 Buyse (10.1016/j.nmd.2019.02.002_bib0017) 2011; 21 Pane (10.1016/j.nmd.2019.02.002_bib0023) 2015; 25 Hogrel (10.1016/j.nmd.2019.02.002_bib0029) 2015; 16 (10.1016/j.nmd.2019.02.002_bib0035) 2017 Mayhew (10.1016/j.nmd.2019.02.002_bib0022) 2013; 55 McDonald (10.1016/j.nmd.2019.02.002_bib0021) 2018; 28 Buyse (10.1016/j.nmd.2019.02.002_bib0039) 2015; 385 Miller (10.1016/j.nmd.2019.02.002_bib0030) 2005; 26 Quanjer (10.1016/j.nmd.2019.02.002_bib0032) 2012; 40 Servais (10.1016/j.nmd.2019.02.002_bib0028) 2013; 23 Buyse (10.1016/j.nmd.2019.02.002_bib0019) 2015; 385 Finder (10.1016/j.nmd.2019.02.002_bib0020) 2017; 196 10.1016/j.nmd.2019.02.002_bib0015 Khirani (10.1016/j.nmd.2019.02.002_bib0036) 2014; 49 Birnkrant (10.1016/j.nmd.2019.02.002_bib0010) 2018; 17 10.1016/j.nmd.2019.02.002_bib0014 Pane (10.1016/j.nmd.2019.02.002_bib0025) 2014; 9 Mendell (10.1016/j.nmd.2019.02.002_bib0002) 2012; 71 Blake (10.1016/j.nmd.2019.02.002_bib0004) 2002; 82 Ricotti (10.1016/j.nmd.2019.02.002_bib0042) 2016; 87 Servais (10.1016/j.nmd.2019.02.002_bib0045) 2015; 2 Matthews (10.1016/j.nmd.2019.02.002_bib0013) 2016; 5 Jean (10.1016/j.nmd.2019.02.002_bib0001) 2014; 24 Birnkrant (10.1016/j.nmd.2019.02.002_bib0012) 2018; 17 Connolly (10.1016/j.nmd.2019.02.002_bib0038) 2016; 54 Ricotti (10.1016/j.nmd.2019.02.002_bib0041) 2016; 11 LoMauro (10.1016/j.nmd.2019.02.002_bib0009) 2015; 11 van den Bergen (10.1016/j.nmd.2019.02.002_bib0044) 2014; 1 Bello (10.1016/j.nmd.2019.02.002_bib0043) 2016; 87 |
References_xml | – year: 2016 ident: bib0016 article-title: FDA Grants Accelerated Approval to First Drug for Duchenne Muscular Dystrophy – volume: 48 start-page: 912 year: 2013 end-page: 920 ident: bib0018 article-title: Effects of glucocorticoids and idebenone on respiratory function in patients with duchenne muscular dystrophy publication-title: Pediatr. Pulmonol. – volume: 23 start-page: 682 year: 2013 end-page: 689 ident: bib0003 article-title: 195th ENMC International Workshop: newborn screening for Duchenne muscular dystrophy 14–16th December, 2012, Naarden, The Netherlands publication-title: Neuromuscul. Disord. – volume: 21 start-page: 396 year: 2011 end-page: 405 ident: bib0017 article-title: Idebenone as a novel, therapeutic approach for Duchenne muscular dystrophy: results from a 12 month, double-blind, randomized placebo-controlled trial publication-title: Neuromuscul. Disord. – volume: 86 start-page: 1022 year: 2016 end-page: 1030 ident: bib0040 article-title: Longitudinal functional and NMR assessment of upper limbs in Duchenne muscular dystrophy publication-title: Neurology – volume: 35 start-page: 126 year: 2003 end-page: 132 ident: bib0031 article-title: Maximal static respiratory pressures in children and adolescents publication-title: Pediatr. Pulmonol. – volume: 23 start-page: 139 year: 2013 end-page: 148 ident: bib0028 article-title: Innovative methods to assess upper limb strength and function in non-ambulant Duchenne patients publication-title: Neuromuscul. Disord. – volume: 11 start-page: 1475 year: 2015 end-page: 1488 ident: bib0009 article-title: Assessment and management of respiratory function in patients with Duchenne muscular dystrophy: current and emerging options publication-title: Ther. Clin. Risk Manag. – reference: . 2017. – volume: 28 start-page: 897 year: 2018 end-page: 909 ident: bib0021 article-title: Longitudinal pulmonary function testing outcome measures in Duchenne muscular dystrophy: long-term natural history with and without glucocorticoids publication-title: Neuromuscul. Disord. – volume: 385 start-page: 1748 year: 2015 end-page: 1757 ident: bib0039 article-title: Efficacy of idebenone on respiratory function in patients with Duchenne muscular dystrophy not using glucocorticoids (DELOS): a double-blind randomised placebo-controlled phase 3 trial publication-title: Lancet – volume: 24 start-page: 201 year: 2014 end-page: 206 ident: bib0024 article-title: Reliability of the performance of upper limb assessment in Duchenne muscular dystrophy publication-title: Neuromuscul. Disord. – reference: Administration USFaD, – volume: 87 start-page: 401 year: 2016 end-page: 409 ident: bib0043 article-title: DMD genotypes and loss of ambulation in the CINRG Duchenne Natural History Study publication-title: Neurology – volume: 55 start-page: 1038 year: 2013 end-page: 1045 ident: bib0022 article-title: Development of the performance of the upper limb module for Duchenne muscular dystrophy publication-title: Dev. Med. Child Neurol. – volume: 40 start-page: 1324 year: 2012 end-page: 1343 ident: bib0032 article-title: Multi-ethnic reference values for spirometry for the 3–95-yr age range: the global lung function 2012 equations publication-title: Eur. Respir. J. – year: 2017 ident: bib0035 article-title: Stata Statistical Software – volume: 71 start-page: 304 year: 2012 end-page: 313 ident: bib0002 article-title: Evidence-based path to newborn screening for Duchenne muscular dystrophy publication-title: Ann. Neurol. – volume: 50 start-page: 487 year: 2015 end-page: 494 ident: bib0037 article-title: Characterization of pulmonary function in Duchenne muscular dystrophy publication-title: Pediatr. Pulmonol. – volume: 54 start-page: 681 year: 2016 end-page: 689 ident: bib0038 article-title: Clinical trial readiness in non-ambulatory boys and men with duchenne muscular dystrophy: MDA-DMD network follow-up publication-title: Muscle Nerve – volume: 2 start-page: 269 year: 2015 end-page: 279 ident: bib0045 article-title: Non-ambulant duchenne patients theoretically treatable by exon 53 skipping have severe phenotype publication-title: J. Neuromuscul. Dis. – volume: 17 start-page: 445 year: 2018 end-page: 455 ident: bib0012 article-title: Diagnosis and management of Duchenne muscular dystrophy, part 3: primary care, emergency management, psychosocial care, and transitions of care across the lifespan publication-title: Lancet Neurol. – volume: 26 start-page: 319 year: 2005 end-page: 338 ident: bib0030 article-title: Standardisation of spirometry publication-title: Eur. Respir. J. – volume: 142 start-page: S82 year: 2018 end-page: S89 ident: bib0006 article-title: Orthopedic and surgical management of the patient with Duchenne muscular dystrophy publication-title: Pediatrics – volume: 17 start-page: 347 year: 2018 end-page: 361 ident: bib0010 article-title: Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management publication-title: Lancet Neurol. – volume: 25 start-page: 749 year: 2015 end-page: 753 ident: bib0023 article-title: Benefits of glucocorticoids in non-ambulant boys/men with Duchenne muscular dystrophy: a multicentric longitudinal study using the performance of upper limb test publication-title: Neuromuscul. Disord. – volume: 24 start-page: 10 year: 2014 ident: bib0001 article-title: A systematic review and meta-analysis of the epidemiology of Duchenne and Becker muscular dystrophy publication-title: Neuromuscul. Disord. – volume: 82 start-page: 291 year: 2002 end-page: 329 ident: bib0004 article-title: Function and genetics of dystrophin and dystrophin-related proteins in muscle publication-title: Physiol. Rev. – volume: 67 start-page: 2533 year: 2016 end-page: 2546 ident: bib0008 article-title: Dystrophin-deficient cardiomyopathy publication-title: J. Am. Coll. Cardiol. – volume: 17 start-page: 251 year: 2018 end-page: 267 ident: bib0011 article-title: Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management publication-title: Lancet Neurol. – volume: 13 year: 2018 ident: bib0033 article-title: Upper limb function in Duchenne muscular dystrophy: 24 month longitudinal data publication-title: PLoS One – reference: Excellence N-NIfHaC. Ataluren for Treating Duchenne Muscular Dystrophy with a Nonsense Mutation in the Dystrophin Gene. In: Excellence N-N I f H a C, 2016. – volume: 9 start-page: e83400 year: 2014 ident: bib0025 article-title: 6 Minute walk test in Duchenne MD patients with different mutations: 12 month changes publication-title: PLoS One – volume: 385 start-page: 1748 year: 2015 end-page: 1757 ident: bib0019 article-title: Efficacy of idebenone on respiratory function in patients with Duchenne muscular dystrophy not using glucocorticoids (DELOS): a double-blind randomised placebo-controlled phase 3 trial publication-title: Lancet – volume: 16 start-page: 139 year: 2015 ident: bib0029 article-title: Grip strength measured by high precision dynamometry in healthy subjects from 5 to 80 years publication-title: BMC Musculoskelet. Disord. – volume: 25 start-page: 1116 year: 2010 end-page: 1129 ident: bib0005 article-title: Change in natural history of Duchenne muscular dystrophy with long-term corticosteroid treatment: implications for management publication-title: J. Child. Neurol. – volume: 12 start-page: 926 year: 2002 end-page: 929 ident: bib0007 article-title: Survival in Duchenne muscular dystrophy: improvements in life expectancy since 1967 and the impact of home nocturnal ventilation publication-title: Neuromuscul. Disord. – volume: 10 year: 2015 ident: bib0034 article-title: Upper limb strength and function changes during a one-year follow-up in non-ambulant patients with Duchenne Muscular Dystrophy: an observational multicenter trial publication-title: PLoS One – volume: 87 start-page: 149 year: 2016 end-page: 155 ident: bib0042 article-title: The NorthStar ambulatory assessment in Duchenne muscular dystrophy: considerations for the design of clinical trials publication-title: J. Neurol. Neurosurg. Psychiatry – volume: 11 year: 2016 ident: bib0041 article-title: Upper limb evaluation in Duchenne muscular dystrophy: fat-water quantification by MRI, muscle force and function define endpoints for clinical trials publication-title: PLoS One – volume: 5 year: 2016 ident: bib0013 article-title: Corticosteroids for the treatment of Duchenne muscular dystrophy publication-title: Cochrane Database Syst. Rev. – volume: 1 start-page: 91 year: 2014 end-page: 94 ident: bib0044 article-title: Prolonged ambulation in Duchenne patients with a mutation amenable to exon 44 skipping publication-title: J. Neuromuscul. Dis. – volume: 53 start-page: 545 year: 2016 end-page: 554 ident: bib0026 article-title: Reachable workspace and performance of upper limb (PUL) in duchenne muscular dystrophy publication-title: Muscle Nerve – volume: 9 start-page: 77 year: 2010 end-page: 93 ident: bib0027 article-title: Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management publication-title: Lancet Neurol. – volume: 196 start-page: 512 year: 2017 end-page: 519 ident: bib0020 article-title: Pulmonary endpoints in Duchenne muscular dystrophy. A workshop summary publication-title: Am. J. Respir. Crit. Care Med. – volume: 49 start-page: 473 year: 2014 end-page: 481 ident: bib0036 article-title: Respiratory muscle decline in Duchenne muscular dystrophy publication-title: Pediatr. Pulmonol. – volume: 11 year: 2016 ident: 10.1016/j.nmd.2019.02.002_bib0041 article-title: Upper limb evaluation in Duchenne muscular dystrophy: fat-water quantification by MRI, muscle force and function define endpoints for clinical trials publication-title: PLoS One doi: 10.1371/journal.pone.0162542 – volume: 71 start-page: 304 year: 2012 ident: 10.1016/j.nmd.2019.02.002_bib0002 article-title: Evidence-based path to newborn screening for Duchenne muscular dystrophy publication-title: Ann. Neurol. doi: 10.1002/ana.23528 – volume: 23 start-page: 139 year: 2013 ident: 10.1016/j.nmd.2019.02.002_bib0028 article-title: Innovative methods to assess upper limb strength and function in non-ambulant Duchenne patients publication-title: Neuromuscul. Disord. doi: 10.1016/j.nmd.2012.10.022 – volume: 9 start-page: 77 year: 2010 ident: 10.1016/j.nmd.2019.02.002_bib0027 article-title: Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management publication-title: Lancet Neurol. doi: 10.1016/S1474-4422(09)70271-6 – ident: 10.1016/j.nmd.2019.02.002_bib0014 – volume: 385 start-page: 1748 year: 2015 ident: 10.1016/j.nmd.2019.02.002_bib0019 article-title: Efficacy of idebenone on respiratory function in patients with Duchenne muscular dystrophy not using glucocorticoids (DELOS): a double-blind randomised placebo-controlled phase 3 trial publication-title: Lancet doi: 10.1016/S0140-6736(15)60025-3 – volume: 13 year: 2018 ident: 10.1016/j.nmd.2019.02.002_bib0033 article-title: Upper limb function in Duchenne muscular dystrophy: 24 month longitudinal data publication-title: PLoS One doi: 10.1371/journal.pone.0199223 – volume: 25 start-page: 749 year: 2015 ident: 10.1016/j.nmd.2019.02.002_bib0023 article-title: Benefits of glucocorticoids in non-ambulant boys/men with Duchenne muscular dystrophy: a multicentric longitudinal study using the performance of upper limb test publication-title: Neuromuscul. Disord. doi: 10.1016/j.nmd.2015.07.009 – volume: 9 start-page: e83400 year: 2014 ident: 10.1016/j.nmd.2019.02.002_bib0025 article-title: 6 Minute walk test in Duchenne MD patients with different mutations: 12 month changes publication-title: PLoS One doi: 10.1371/journal.pone.0083400 – volume: 40 start-page: 1324 year: 2012 ident: 10.1016/j.nmd.2019.02.002_bib0032 article-title: Multi-ethnic reference values for spirometry for the 3–95-yr age range: the global lung function 2012 equations publication-title: Eur. Respir. J. doi: 10.1183/09031936.00080312 – year: 2017 ident: 10.1016/j.nmd.2019.02.002_bib0035 – year: 2016 ident: 10.1016/j.nmd.2019.02.002_bib0016 – volume: 21 start-page: 396 year: 2011 ident: 10.1016/j.nmd.2019.02.002_bib0017 article-title: Idebenone as a novel, therapeutic approach for Duchenne muscular dystrophy: results from a 12 month, double-blind, randomized placebo-controlled trial publication-title: Neuromuscul. Disord. doi: 10.1016/j.nmd.2011.02.016 – volume: 23 start-page: 682 year: 2013 ident: 10.1016/j.nmd.2019.02.002_bib0003 article-title: 195th ENMC International Workshop: newborn screening for Duchenne muscular dystrophy 14–16th December, 2012, Naarden, The Netherlands publication-title: Neuromuscul. Disord. doi: 10.1016/j.nmd.2013.05.008 – volume: 385 start-page: 1748 year: 2015 ident: 10.1016/j.nmd.2019.02.002_bib0039 article-title: Efficacy of idebenone on respiratory function in patients with Duchenne muscular dystrophy not using glucocorticoids (DELOS): a double-blind randomised placebo-controlled phase 3 trial publication-title: Lancet doi: 10.1016/S0140-6736(15)60025-3 – volume: 87 start-page: 401 year: 2016 ident: 10.1016/j.nmd.2019.02.002_bib0043 article-title: DMD genotypes and loss of ambulation in the CINRG Duchenne Natural History Study publication-title: Neurology doi: 10.1212/WNL.0000000000002891 – volume: 67 start-page: 2533 year: 2016 ident: 10.1016/j.nmd.2019.02.002_bib0008 article-title: Dystrophin-deficient cardiomyopathy publication-title: J. Am. Coll. Cardiol. doi: 10.1016/j.jacc.2016.02.081 – volume: 17 start-page: 347 year: 2018 ident: 10.1016/j.nmd.2019.02.002_bib0010 article-title: Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management publication-title: Lancet Neurol. doi: 10.1016/S1474-4422(18)30025-5 – volume: 53 start-page: 545 year: 2016 ident: 10.1016/j.nmd.2019.02.002_bib0026 article-title: Reachable workspace and performance of upper limb (PUL) in duchenne muscular dystrophy publication-title: Muscle Nerve doi: 10.1002/mus.24894 – volume: 82 start-page: 291 year: 2002 ident: 10.1016/j.nmd.2019.02.002_bib0004 article-title: Function and genetics of dystrophin and dystrophin-related proteins in muscle publication-title: Physiol. Rev. doi: 10.1152/physrev.00028.2001 – volume: 35 start-page: 126 year: 2003 ident: 10.1016/j.nmd.2019.02.002_bib0031 article-title: Maximal static respiratory pressures in children and adolescents publication-title: Pediatr. Pulmonol. doi: 10.1002/ppul.10217 – volume: 24 start-page: 10 year: 2014 ident: 10.1016/j.nmd.2019.02.002_bib0001 article-title: A systematic review and meta-analysis of the epidemiology of Duchenne and Becker muscular dystrophy publication-title: Neuromuscul. Disord. – volume: 196 start-page: 512 year: 2017 ident: 10.1016/j.nmd.2019.02.002_bib0020 article-title: Pulmonary endpoints in Duchenne muscular dystrophy. A workshop summary publication-title: Am. J. Respir. Crit. Care Med. doi: 10.1164/rccm.201703-0507WS – volume: 55 start-page: 1038 year: 2013 ident: 10.1016/j.nmd.2019.02.002_bib0022 article-title: Development of the performance of the upper limb module for Duchenne muscular dystrophy publication-title: Dev. Med. Child Neurol. doi: 10.1111/dmcn.12213 – volume: 87 start-page: 149 year: 2016 ident: 10.1016/j.nmd.2019.02.002_bib0042 article-title: The NorthStar ambulatory assessment in Duchenne muscular dystrophy: considerations for the design of clinical trials publication-title: J. Neurol. Neurosurg. Psychiatry – volume: 26 start-page: 319 year: 2005 ident: 10.1016/j.nmd.2019.02.002_bib0030 article-title: Standardisation of spirometry publication-title: Eur. Respir. J. doi: 10.1183/09031936.05.00034805 – volume: 142 start-page: S82 year: 2018 ident: 10.1016/j.nmd.2019.02.002_bib0006 article-title: Orthopedic and surgical management of the patient with Duchenne muscular dystrophy publication-title: Pediatrics doi: 10.1542/peds.2018-0333J – volume: 24 start-page: 201 year: 2014 ident: 10.1016/j.nmd.2019.02.002_bib0024 article-title: Reliability of the performance of upper limb assessment in Duchenne muscular dystrophy publication-title: Neuromuscul. Disord. doi: 10.1016/j.nmd.2013.11.014 – volume: 10 year: 2015 ident: 10.1016/j.nmd.2019.02.002_bib0034 article-title: Upper limb strength and function changes during a one-year follow-up in non-ambulant patients with Duchenne Muscular Dystrophy: an observational multicenter trial publication-title: PLoS One – volume: 48 start-page: 912 year: 2013 ident: 10.1016/j.nmd.2019.02.002_bib0018 article-title: Effects of glucocorticoids and idebenone on respiratory function in patients with duchenne muscular dystrophy publication-title: Pediatr. Pulmonol. doi: 10.1002/ppul.22688 – volume: 1 start-page: 91 year: 2014 ident: 10.1016/j.nmd.2019.02.002_bib0044 article-title: Prolonged ambulation in Duchenne patients with a mutation amenable to exon 44 skipping publication-title: J. Neuromuscul. Dis. doi: 10.3233/JND-140002 – ident: 10.1016/j.nmd.2019.02.002_bib0015 – volume: 5 issue: 5 year: 2016 ident: 10.1016/j.nmd.2019.02.002_bib0013 article-title: Corticosteroids for the treatment of Duchenne muscular dystrophy publication-title: Cochrane Database Syst. Rev. – volume: 16 start-page: 139 year: 2015 ident: 10.1016/j.nmd.2019.02.002_bib0029 article-title: Grip strength measured by high precision dynamometry in healthy subjects from 5 to 80 years publication-title: BMC Musculoskelet. Disord. doi: 10.1186/s12891-015-0612-4 – volume: 17 start-page: 445 year: 2018 ident: 10.1016/j.nmd.2019.02.002_bib0012 article-title: Diagnosis and management of Duchenne muscular dystrophy, part 3: primary care, emergency management, psychosocial care, and transitions of care across the lifespan publication-title: Lancet Neurol. doi: 10.1016/S1474-4422(18)30026-7 – volume: 2 start-page: 269 year: 2015 ident: 10.1016/j.nmd.2019.02.002_bib0045 article-title: Non-ambulant duchenne patients theoretically treatable by exon 53 skipping have severe phenotype publication-title: J. Neuromuscul. Dis. doi: 10.3233/JND-150100 – volume: 28 start-page: 897 issue: 11 year: 2018 ident: 10.1016/j.nmd.2019.02.002_bib0021 article-title: Longitudinal pulmonary function testing outcome measures in Duchenne muscular dystrophy: long-term natural history with and without glucocorticoids publication-title: Neuromuscul. Disord. doi: 10.1016/j.nmd.2018.07.004 – volume: 49 start-page: 473 year: 2014 ident: 10.1016/j.nmd.2019.02.002_bib0036 article-title: Respiratory muscle decline in Duchenne muscular dystrophy publication-title: Pediatr. Pulmonol. doi: 10.1002/ppul.22847 – volume: 25 start-page: 1116 year: 2010 ident: 10.1016/j.nmd.2019.02.002_bib0005 article-title: Change in natural history of Duchenne muscular dystrophy with long-term corticosteroid treatment: implications for management publication-title: J. Child. Neurol. doi: 10.1177/0883073810371004 – volume: 54 start-page: 681 year: 2016 ident: 10.1016/j.nmd.2019.02.002_bib0038 article-title: Clinical trial readiness in non-ambulatory boys and men with duchenne muscular dystrophy: MDA-DMD network follow-up publication-title: Muscle Nerve doi: 10.1002/mus.25089 – volume: 50 start-page: 487 year: 2015 ident: 10.1016/j.nmd.2019.02.002_bib0037 article-title: Characterization of pulmonary function in Duchenne muscular dystrophy publication-title: Pediatr. Pulmonol. doi: 10.1002/ppul.23172 – volume: 11 start-page: 1475 year: 2015 ident: 10.1016/j.nmd.2019.02.002_bib0009 article-title: Assessment and management of respiratory function in patients with Duchenne muscular dystrophy: current and emerging options publication-title: Ther. Clin. Risk Manag. – volume: 12 start-page: 926 year: 2002 ident: 10.1016/j.nmd.2019.02.002_bib0007 article-title: Survival in Duchenne muscular dystrophy: improvements in life expectancy since 1967 and the impact of home nocturnal ventilation publication-title: Neuromuscul. Disord. doi: 10.1016/S0960-8966(02)00140-2 – volume: 17 start-page: 251 year: 2018 ident: 10.1016/j.nmd.2019.02.002_bib0011 article-title: Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management publication-title: Lancet Neurol. doi: 10.1016/S1474-4422(18)30024-3 – volume: 86 start-page: 1022 year: 2016 ident: 10.1016/j.nmd.2019.02.002_bib0040 article-title: Longitudinal functional and NMR assessment of upper limbs in Duchenne muscular dystrophy publication-title: Neurology doi: 10.1212/WNL.0000000000002464 |
RestrictionsOnAccess | restricted access |
SSID | ssj0015767 |
Score | 2.4043055 |
Snippet | •This study contributes to the natural history of DMD, linking the ambulant and non-ambulant phases.•Respiratory measurements, upper limb function, pinch and... The field of translational research in Duchenne muscular dystrophy (DMD) has been transformed in the last decade by a number of therapeutic targets, mostly... |
SourceID | liege proquest pubmed crossref elsevier |
SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 261 |
SubjectTerms | Adolescent Cardiovascular & respiratory systems Child Child, Preschool Composite endpoint Duchenne muscular dystrophy Europe forced vital capacity Human health sciences Humans Male Mobility Limitation Motor Activity - physiology Muscle Strength - physiology Muscle, Skeletal - physiopathology Muscular Dystrophy, Duchenne - complications Muscular Dystrophy, Duchenne - physiopathology Neurologie Neurology Outcome Assessment, Health Care peak expiratory flow Pediatrics Prospective Studies pulmonary function Pédiatrie Respiration Respiration Disorders - etiology Respiration Disorders - physiopathology Respiratory Function Tests Sciences de la santé humaine Systèmes cardiovasculaire & respiratoire Upper Extremity - physiopathology Upper limb function and strength |
Title | Respiratory and upper limb function as outcome measures in ambulant and non-ambulant subjects with Duchenne muscular dystrophy: A prospective multicentre study |
URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0960896618313798 https://dx.doi.org/10.1016/j.nmd.2019.02.002 https://www.ncbi.nlm.nih.gov/pubmed/30852071 https://www.proquest.com/docview/2190120661 http://orbi.ulg.ac.be/handle/2268/244031 |
Volume | 29 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1JixUxEA7DDIgXcfe5DBE8ifF1OunN22N0eCrOQR2YW0jSydDSy-N1R_DiX_GvWkkv4mFG8NYdqiBJVSpfUksQesGTPFMZT4jNopzwIjcEzioJMQCdbWptGclQ7fMs3Z7zDxfJxQE6mXNhfFjlZPtHmx6s9dSynmZzvauq9RcPvnNA66CUlGWFT_jlPPNa_vrnEuZBAU-HlGkgJp569myGGK-28cVCaTGW7Yyv2puOau_AvhqDhr3o9Da6NYFIvBn7eQcdmPYuuvFpcpPfQ78-_3GgY9mW2O12Zo_rqlHYb2ReGFj2uHMDjNvgZrwo7HEFzY1yNUx34Gu7liwNvVP-0qbH_u4Wv3UgbjDSuHFjLCsuf_TDvgOxvcEbDGOYkzhxCFoMUaAGh3K299H56buvJ1syvcRANEzpQHJrtaXSxswYTnUGqLI0WSoZL5SxRmdRolNapnAyL0qmABJIaaiyOS8LVljKHqBD6LF5hLBUSWJzyW2iLdgPKvOyZDrjktpUK8VWKJplIPRUpty_llGLOR7tmwCxCS82EcUCxLZCLxeW3Vij4zrieBasmJNPwVwK2EGuY-IL01_a-S-2V0FzRLdXlfgeC1_LO3y7-lJILZQRAH9zARgLjOsKPZ8VTMAi954b2ZrO9SL2sM0X3geah6PmLSNlAJpjAIqP_6-PT9BN_zcGIz1Fh8PemWeAswZ1HBbSMTravP-4PfsNMBwquA |
linkProvider | Elsevier |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELbKrgRcUHkvtGAkToho83ASh9uqpdrSdg_QSr1ZtmNXQXmsNjESv4a_yth5IA4tErfI8Ui2Zzz-7Bl_Rug9iWkqUhJ7OvWpRzKqPNirxJ4C6KwTrXOfO7bPTbK-Il-u4-s9dDTehbFplYPv732689ZDyXIYzeW2KJbfLPimgNbBKIMozeg9NLfsVPEMzVenZ-vNFEwASO1uTUN9zwqMwU2X5lVXli80yHrmzvC25Wle2hj27TDULUcn--jRgCPxqm_qY7Sn6ifo_sUQKX-Kfn39E0PHvM6x2W7VDpdFJbBdy6w-MG9xYzrousJVf1bY4gKKK2FKGHEnVze1NxW0Rthzmxbb41t8bEDj4KdxZfp0Vpz_bLtdA5r7hFcY-jDe48Qub9ElgirsGG2foauTz5dHa294jMGThKSdR7WWOuA6jJQigUwBWOYqTXhEMqG0kqkfyyTIE9icZ3kkABVwrgKhKcmzKNNB9BzNoMXqJcJcxLGmnOhYanAhAad5HsmU8EAnUohogfxRB0wOTOX2wYySjSlp3xmojVm1MT9koLYF-jCJbHuajrsqh6Ni2Xj_FDwmg0XkLiEyCf1loP8S--gshzU7UbAfIbN03u7blDeMSyYUAwRMGcAs8K8L9G40MAbz3AZveK0a07LQIjfLvQ91XvSWN_U0AtwcAlZ89X9tfIserC8vztn56ebsNXpo__S5SQdo1u2MOgTY1Yk3w7T6DUrjLWk |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Respiratory+and+upper+limb+function+as+outcome+measures+in+ambulant+and+non-ambulant+subjects+with+Duchenne+muscular+dystrophy%3A+A+prospective+multicentre+study&rft.jtitle=Neuromuscular+disorders+%3A+NMD&rft.au=Ricotti%2C+V&rft.au=Selby%2C+V&rft.au=Ridout%2C+D&rft.au=Domingos%2C+J&rft.date=2019-04-01&rft.issn=1873-2364&rft.eissn=1873-2364&rft.volume=29&rft.issue=4&rft.spage=261&rft_id=info:doi/10.1016%2Fj.nmd.2019.02.002&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0960-8966&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0960-8966&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0960-8966&client=summon |